France Antiemetics Drugs Market

France Antiemetics Drugs Market Insights Forecasts to 2035

• The France Antiemetics Drugs Market Size Was Estimated at USD 344.1 Million in 2024.
• The France Antiemetics Drugs Market Size is Expected to Grow at a CAGR of Around 5.5% from 2025 to 2035.
• The France Antiemetics Drugs Market Size is Expected to Reach USD 619.8 Million by 2035.

According to a research report published by decision advisor & Consulting, the France Antiemetics Drugs Market Size is projected to reach USD 619.8 million by 2035, growing at a CAGR of 5.5% from 2025 to 2035. The France antiemetics drugs market is driven by the increasing prevalence of conditions that cause nausea and vomiting, such as cancer, chemotherapy, and gastroenteritis. Other key drivers include advancements in drug development and a growing awareness of the need to manage these symptoms effectively to improve patients' quality of life. 

Market Overview

The France antiemetics drugs market refers to the industry dedicated to manufacturing and distribution of pharmaceutical medications used to prevent and treat nausea and vomiting in France, It includes drugs like serotonin-receptor antagonists, dopamine antagonists, and others, driven by factors like a growing cancer patient population undergoing chemotherapy, increased usage in treating motion sickness and post-operative nausea, and the availability of both over-the-counter (OTC) and prescription drugs.

The France antiemetics market is expected to see continuous growth in the future due to increased demand by rising cancer rates and chemotherapy, advancements in drug development leading to novel therapies, and a growing application in managing side effects from various medical treatments. An increase in other conditions that trigger nausea and vomiting, such as gastroenteritis, motion sickness, and post-operative nausea and vomiting (PONV), also contributes to market growth.

The ongoing research and development activities are leading to the introduction of new and more effective antiemetic drugs with improved efficacy and fewer side effects. Major players in the antiemetics market, including those active in France like Pfizer and GSK, are continually engaged in R&D and securing drug approvals. This leads to new products entering the market, Such as an improved formulation of a fixed-dose combination pill of an NK1 antagonist and a 5-HT3 antagonist, simplifying the dosing regimen and improving patient adherence. And a transdermal patch or a subcutaneous injection, providing slow, controlled release of the drug for up to several days, which helps manage delayed chemotherapy-induced nausea and vomiting (CINV) more effectively than other forms.

Report Coverage

This research report categorizes the market for the France antiemetics drugs market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the France antiemetics drugs market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the France antiemetics drugs market.

Driving Factors

The main drivers of the antiemetics drugs market in France include the increasing prevalence of conditions that cause nausea and vomiting, such as cancer, gastroenteritis, coupled with an aging population and rising healthcare expenditure. The rising rates of cancer in France mean more patients require chemotherapy, which frequently causes nausea and vomiting, boosting the demand for antiemetics to manage side effects. Other factors include increased surgical procedures, advances in R&D and new product approvals, and the growing accessibility of drugs through improved healthcare infrastructure. 

Restraining Factors

The main restraining factors for the antiemetics drugs market in France include adverse effects of the drugs, such as constipation, fatigue, muscle spasms, and dry mouth, pricing challenges from generic competition, and a high volume of drug shortages due to supply chain issues and manufacturing capacity problems. 

Market Segmentation

The France antiemetics drugs market share is categorized by drug type, application, and end user

• The serotonin-receptor antagonists segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The France antiemetics drugs market is segmented by drug type into serotonin-receptor antagonists, anticholinergics, dopamine receptor antagonists, neurokinin receptor antagonists, and others. Among these, the serotonin-receptor antagonists segment accounted for the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The serotonin-receptor antagonists segmental growth is due to their high efficacy and favorable safety profile in managing nausea and vomiting from chemotherapy, radiation therapy, and anesthesia, a market segment that has been driven by the growing prevalence of cancer in France. 

• The chemotherapy segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.  

The France antiemetics drugs market is segmented by application into chemotherapy, gastroenteritis, post-operative surgery, and others. Among these, the chemotherapy segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The chemotherapy segmental dominance is due to the high incidence of cancer, the frequent use of antiemetic drugs as a standard part of treatment to manage chemotherapy-induced nausea and vomiting, and the necessity of antiemetic drugs to manage the severe nausea and vomiting that are common side effects of aggressive cancer treatments. 

• The retail pharmacies held the largest market share in 2024 and are anticipated to grow at a significant CAGR during the forecast period.

The France antiemetics drugs market is segmented by end user into hospitals, clinics, retail pharmacies, and others. Among these, the retail pharmacies held the largest market share in 2024 and are anticipated to grow at a significant CAGR during the forecast period. The retail pharmacies segmental growth is due to its established store networks, strong over-the-counter (OTC) and prescription accessibility, and the growing demand for self-medication for common conditions like motion sickness and gastroenteritis. Retail pharmacies benefit from widespread accessibility in both urban and semi-urban areas, providing an easy point of care for immediate relief, often with the guidance of pharmacists.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the France antiemetics drugs market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 List of Key Companies

• Glenmark Pharmaceuticals
• Astellas Pharma Inc
• Viatris Inc
• Novartis AG
• GlaxoSmithKline
• Merck & Co., Inc.
• Norgine B.V
• Pfizer Inc
• Johnson & Johnson
• Merck KGaA
• Baxter International Inc
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

In October 2020, Norgine B.V. acquired the European, Australian, and New Zealand rights for Setofilm from (APR) Applied Pharma Research. The Setofilm is an oral dispersible film containing ondansetron, used to prevent and treat nausea and vomiting, and is an alternative to conventional tablets. This acquisition strengthened Norgine's position in major European markets, such as France, for ondansetron film technology.

Market Segment

This study forecasts revenue at the France, regional, and country levels from 2020 to 2035. decision advisor has segmented the France Antiemetics Drugs Market based on the below-mentioned segments:

France Antiemetics Drugs Market, By Drug Type

• Serotonin-Receptor Antagonists
• Anticholinergics
• Dopamine Receptor Antagonists
• Neurokinin Receptor Antagonists
• Others

France Antiemetics Drugs Market, By Application

• Chemotherapy
• Gastroenteritis
• Post-Operative Surgery
• Others

France Antiemetics Drugs Market, By End User

• Hospitals
• Clinics
• Retail Pharmacies
• Others

Frequently Asked Questions (FAQ)

1. What is the CAGR of the France antiemetics drugs market?

The France antiemetics drugs market size is expected to grow at a CAGR of around 5.5% from 2024 to 2035.

2. What is the France antiemetics drugs market size in 2024?

The France antiemetics drugs market size was estimated at USD 344.1 million in 2024.

3. What is the projected market size of the France antiemetics drugs market by 2035?

The France antiemetics drugs market size is expected to reach USD 619.8 million by 2035.

4. What are the main segments of the France antiemetics drugs market?

The France antiemetics drugs market share is segmented based on drug type, application, and end user.

5. What are some drivers contributing to market growth?

France antiemetics drugs market is driven by the increasing prevalence of conditions that cause nausea and vomiting, such as cancer, gastroenteritis. Other factors include increased surgical procedures, advances in R&D and new product approvals, and the growing accessibility of drugs through improved healthcare infrastructure.